Daiichi Sankyo receives a wide range of requests from society for responding to unmet medical needs,*1 providing a stable supply of top-quality pharmaceutical products, improving access to pharmaceuticals,*2 and environment, social, and governance (ESG) activities, all of which contribute to the Sustainable Development Goals (SDGs). We work on efforts to enhance our long-term corporate value, as well as initiatives to realize a sustainable society, through leveraging various capitals (i.e., financial, manufactured, intellectual, human, social and relationship, and natural capital).
The basis of our value creation is our sustainability initiative, which includes to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs, while taking advantage of our strengths in Science & Technology, Global Organization & Talent, and Presence in Japan, as well as to address social and environmental issues. For the materiality of these activities (high-priority issues), we have identified materiality issues related to: (i) business including creation of innovative pharmaceuticals; and (ii) our business foundations, such as governance and environmental management. By continuing this cycle of our value creation process, we will sustainably improve our corporate value, and we will provide the values in a well-balanced manner to our stakeholders and society, including patients, their families, healthcare professionals, our shareholders and investors, business partners, employees and local communities.
- *1Medical needs for effective treatment and drugs yet to be developed
- *2Pharmaceuticals needed by patients being delivered sufficiently and consistently
An enlargeable image opens in a separate window